HDAC9 and non-small cell lung carcinoma: MS-275 therapy has been shown to overcome paclitaxel resistance, suggesting that HDAC inhibitors may have a therapeutic potential in treating FBXW7- deficient NSCLC with invasive paclitaxel-resistant (15).